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Clyde W. Yancy, MD, MSCSEE PAGE 553T he landmark STICH (Surgical Treatment ofIschemic Heart Failure) trial was a disappoint-ment—a worthy hypothesis but difﬁcult
execution with unrewarding results (1). STICH posed
2 fundamental questions: is surgical revascularization
for ischemic heart failure (HF) with reduced ejection
fraction (EF) preferable to medical therapy; and
does surgical reverse remodeling therapy change
the natural history of ischemic heart failure compared
to medical therapy? Although largely accepted as
dictum, surgical revascularization for multivessel cor-
onary artery disease and reduced EF emanated from
databases addressing, at best, mildly reduced left ven-
tricular ejection fraction (LVEF) or mild to moderate
clinical HF. Our current threshold for reduced EF HF
(i.e., LVEF < 0.40) was not a consideration in the
earlier CASS (Coronary Artery Surgical Study) and
European surgical studies (2). Thus, both of these
questions were appropriate. To be clear, the predicate
data, consistently used now to guide everyday prac-
tice, addressing the surgical treatment of ischemic
heart disease did not address signiﬁcantly reduced
EF phenotypes and, beyond anecdotal and uncon-
trolled experiential data, did not provide an answer
to address surgical geometric modiﬁcation of the left
ventricle. This evidence gap persisted for decades.
The results that have since emerged from STICH,
including the data addressing viability, provided di-
rection for surgical reverse remodeling, (generally
not indicated) but left us in a quandary regarding sur-
gical treatment of reduced EF HF due to ischemic heart
disease. The primary results of STICH revealed no dif-
ferences in mortality between surgical and medical
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regarding the utility of viability testing to discriminate
between surgical and medical therapy.
The recent American College of Cardiology Foun-
dation/American Heart Association 2013 Heart Failure
Clinical Practice Guidelines (3) highlight the uncer-
tainty which remains: “CABG [coronary artery bypass
graft] or medical therapy is reasonable to improve
morbidity and cardiovascular mortality for patients
with severe LV dysfunction (EF <35%), HF, and sig-
niﬁcant CAD [coronary artery disease] (COR IIa, LOEB).
CABG may be considered with the intent of improving
survival in patients with ischemic heart disease with
severe LV systolic dysfunction (EF <35%), and oper-
able coronary anatomy whether or not viable myocar-
dium is present (COR IIb, LOE B).”
In short, clinical judgment remains the modus
operandi when a physician is confronted with the pa-
tient who has reduced EF HF and ischemic heart
disease.
The new data brought forward in this issue of the
Journal by Panza et al. (4) and the STICH investigators
are therefore illuminating and worthy of our most
careful consideration. A solution may have now
emerged from STICH.Important provisos must be acknowledged before
delving into these new data. First, this was a retro-
spective, nonprespeciﬁed analysis; second, these
were subgroup analyses that, although thoughtfully
derived, remain empirical in construct and impor-
tantly are subject to the power limitations of small
sample size and confounding variables due to lack of
randomization; and third, these ﬁndings have not
been replicated or validated in any other dataset and
may represent both the play of chance and the
consequence of extensive data dredging.
However, we now discover that within the STICH
trial, for those patients with 2 of the 3 generally
agreed upon poor prognostic indicators, namely,
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563multivessel coronary artery disease, reduced EF, and
increased end-systolic volume, there is a 2-year sur-
vival advantage that is statistically (and likely clini-
cally) important that eclipses the early postoperative
mortality risk seen in this higher risk cohort (hazard
ratio [HR]: 0.71, 95% conﬁdence interval [CI]: 0.56 to
0.89; p ¼ 0.004). Given the totality of evidence in
contemporary literature, these data cannot easily be
dismissed. The FREEDOM (Future Revascularization
Evaluation in Patients with Diabetes Mellitus:
Optimal Management of Multi-vessel Disease) trial
would argue that those patients with diabetes, as a
marker of a less-than-good prognosis, and coronary
artery disease beneﬁt from surgical revascularization
(5). Additionally, SYNTAX (Synergy between PCI with
TAXUS and Cardiac Surgery) study data demonstrated
the superiority of surgical revascularization relative
to percutaneous coronary intervention for multi-
vessel or left main coronary artery disease (6). The
resultant SYNTAX score now predicts outcomes
related to anatomical characteristics. In the context
then of these seminal clinical trial results supporting
surgery for higher risk cohorts, data reported by
Panza et al. (4) reach a higher tier of veracity. The
data are even more provocative when one observes
the dismal 2-year outcomes for the medically treated
groupwith 2 or 3 poor prognostic factors (HR: 1.88; 95%
CI: 1.45 to 2.43, p < 0.001). As well, the sensitivity an-
alyses that included per protocol treatments and “as
treated” analyses are concordant. However, when only
1 poor prognostic factor was present, the early opera-
tive mortality associated with bypass surgery was not
overcome at 2 years (HR: 0.88; 95% CI: 0.59 to 1.31;
p ¼ 0.535). Thus, higher risk cohorts did better with
surgery, and lower risk cohorts did better with medical
therapy. An answer from STICH appears to have
materialized; however, as intriguing as these data are,
we must return to our reasons for pause.
These data must be carefully interpreted. The
group of surgeons in STICH had a noteworthy CABG
mortality rate of <5%. We also should recall that
>85% of patients enrolled in STICH were outside the
United States, with important questions recently
raised regarding event rates and standards of care in
non-U.S. populations. Additionally, although the
analysis based on 3-vessel coronary artery disease is
irrefutable, the cut points of an LVEF of 0.27 and an
left ventricular end-systolic volume index (LVESVI)
of 76.8 ml/m2 are debatable and represent retro-
spectively derived median values only. Why not an
LVEF of 0.25 or <0.20 or an LVESVI of >70 ml/m2 or
>90 ml/m2? The data presented indicate the higher
representation of advanced HF (New York Heart As-
sociation functional classiﬁcation III or IV) and atrialﬁbrillation in the higher risk group, but we do not
know which of those important clinical characteris-
tics predicted the observed response to surgical
therapy. Many of us remain befuddled that objective
evidence of ischemia did not predict a surgical
advantage. These data are reported at follow-up of $2
years out to 56 months. We will need to await the
results of the STICH ES (STICH Extension Study) to
better understand longer term outcomes. Finally, in
a contemporary reduced EF HF population, with
a penetration of up to 50% receiving implantable
cardioverter-deﬁbrillator therapy and approximately
20% receiving cardiac resynchronization therapy/
deﬁbrillator therapy, would this survival advantage
remain (7)? Indeed, there aremany caveats to consider.
However, another randomized trial of reduced EF
HF due to ischemic heart disease is not likely. The
imperfection of these data may prevail for some time,
so how do we move beyond these ﬁndings as “hy-
pothesis generating” worthy of a prospective trial
versus provocative new data sufﬁcient to change
clinical practice and accept this solution from STICH?
We should not allow the cloak of uncertainty to deﬁne
these data; we should be more deﬁnitive, if possible,
with these less-than-deﬁnitive data. The authorsmake
a brilliant point, “our ﬁndings should not be consid-
ered as a dogmatic postulate of speciﬁc values to be
used whenmaking decisions on individual patients.”
(4). I agree. The solution now emerging from STICH is
not dogma but reason. The severity of ischemic heart
disease is probably important and surgical treatment
for more advanced disease in an experienced center
with careful deployment of evidence-based medical
and device therapy likely reﬂect optimal therapy for
reduced EF HF due to ischemic heart disease, but the
primary results of STICH remain valid. For all comers,
the decision to operate depends upon the patient’s
anatomy, the comfort of the surgeon, and the context
of best-possible guideline-directed medical therapy
(3). However, for those patients with more advanced
disease as typiﬁed by reasonable descriptors, a more
deliberate revascularization approach, or at least a
more purposeful discussion among all parties, espe-
cially including the patient, might be the pragmatic
solution now provided by STICH.
The guidelines will not change based on these data,
nor should they, but perhaps our practice will.
Finally, a solution emerges from STICH.
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